HK1164159A1 - A composition comprising (-)-trans-3-(5,6-dihydro-4h-pyrrolo [3,2,1-ij] quinolin-1-yl)-4-(1h-indol-3-yl) pyrrolidine-2, 5-dione in combination with sorafenib, sunitinib or erlotinib - Google Patents
A composition comprising (-)-trans-3-(5,6-dihydro-4h-pyrrolo [3,2,1-ij] quinolin-1-yl)-4-(1h-indol-3-yl) pyrrolidine-2, 5-dione in combination with sorafenib, sunitinib or erlotinibInfo
- Publication number
- HK1164159A1 HK1164159A1 HK12105129.9A HK12105129A HK1164159A1 HK 1164159 A1 HK1164159 A1 HK 1164159A1 HK 12105129 A HK12105129 A HK 12105129A HK 1164159 A1 HK1164159 A1 HK 1164159A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- sunitinib
- sorafenib
- erlotinib
- quinolin
- pyrrolo
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15213809P | 2009-02-12 | 2009-02-12 | |
US17047109P | 2009-04-17 | 2009-04-17 | |
PCT/US2010/023893 WO2010093789A2 (en) | 2009-02-12 | 2010-02-11 | Combinational compositions and methods for treatment of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1164159A1 true HK1164159A1 (en) | 2012-09-21 |
Family
ID=42126095
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK12105129.9A HK1164159A1 (en) | 2009-02-12 | 2012-05-24 | A composition comprising (-)-trans-3-(5,6-dihydro-4h-pyrrolo [3,2,1-ij] quinolin-1-yl)-4-(1h-indol-3-yl) pyrrolidine-2, 5-dione in combination with sorafenib, sunitinib or erlotinib |
Country Status (14)
Country | Link |
---|---|
US (2) | US20100297075A1 (xx) |
EP (1) | EP2396003B1 (xx) |
JP (1) | JP5687209B2 (xx) |
KR (1) | KR101620654B1 (xx) |
CN (1) | CN102481299B (xx) |
AU (1) | AU2010213696B2 (xx) |
BR (1) | BRPI1007972A2 (xx) |
CA (1) | CA2752232C (xx) |
HK (1) | HK1164159A1 (xx) |
IL (1) | IL214348A (xx) |
MX (1) | MX2011008584A (xx) |
TW (1) | TWI460178B (xx) |
WO (1) | WO2010093789A2 (xx) |
ZA (1) | ZA201105611B (xx) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2010213696B2 (en) | 2009-02-12 | 2015-10-01 | Arqule, Inc. | A composition comprising (-) -trans-3- (5, 6-dihydro-4H-pyrrolo [3,2,1-ij] quinolin-1-yl)-4-(1H-indol-3-yl) pyrrolidine- 2, 5-dione in combination with a second anti-proliferative agent |
WO2012003421A2 (en) | 2010-07-01 | 2012-01-05 | Arqule, Inc. | Combinational compositions and methods for treatment of cancer |
EP2611443A2 (en) | 2010-09-01 | 2013-07-10 | ArQule, Inc. | Methods for treatment of non-small cell lung cancer |
US8709420B2 (en) * | 2010-12-17 | 2014-04-29 | Glaxosmithkline Intellectual Property Limited | Pharmaceutical combination of pazopanib and topotecan to treat neuroblastoma, osteosarcoma, and rhabdomyosarcoma in a human |
WO2012088491A2 (en) * | 2010-12-23 | 2012-06-28 | Arqule, Inc. | Pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same |
KR20190060879A (ko) | 2011-03-02 | 2019-06-03 | 제롬 쉔타그 | 단독으로 또는 c형 간염 바이러스 감염과 결합되는 간 지방증의 치료를 위한 조성물, 방법 및 진단 |
TW201315470A (zh) * | 2011-07-07 | 2013-04-16 | Arqule Inc | 吡咯並喹啉基-吡咯啶-2,5-二酮調製劑類及製備和使用彼等之方法 |
CA2846630A1 (en) * | 2011-09-19 | 2013-03-28 | Genentech, Inc. | Combination treatments comprising c-met antagonists and b-raf antagonists |
WO2013085902A1 (en) * | 2011-12-05 | 2013-06-13 | The University Of Texas M.D. | Combination therapy methods for treating an inflammatory breast cancer |
TWI594986B (zh) * | 2011-12-28 | 2017-08-11 | Taiho Pharmaceutical Co Ltd | Antineoplastic agent effect enhancer |
JP2015514759A (ja) * | 2012-04-23 | 2015-05-21 | アーキュール,インコーポレイティド | 高純度のピロロキノリニル−ピロール−2,5−ジオンおよびピロロキノリニル−ピロリジン−2,5−ジオン、ならびにそれらの調製方法 |
CN102757435B (zh) * | 2012-06-21 | 2014-05-28 | 成都苑东药业有限公司 | 一种反式-3-吲哚基-4-吲哚并二氮杂卓环庚烷基-2,5-吡咯烷-2,5-二酮化合物及其制备方法 |
BR112016021383A2 (pt) | 2014-03-24 | 2017-10-03 | Genentech Inc | Método para identificar um paciente com câncer que é susceptível ou menos susceptível a responder ao tratamento com um antagonista de cmet, método para identificar um paciente apresentando câncer previamente tratado, método para determinar a expressão do biomarcador hgf, antagonista anti-c-met e seu uso, kit de diagnóstico e seu método de preparo |
PL3388420T3 (pl) * | 2015-12-07 | 2022-12-05 | Hinova Pharmaceuticals Inc. | Związki chinolinowe, sposób ich wytwarzania i ich zastosowanie jako leku stanowiącego inhibitor transportera anionu kwasu moczowego |
MX2021007061A (es) | 2017-02-15 | 2022-10-07 | Taiho Pharmaceutical Co Ltd | Composición farmacéutica que comprende 4-(2-fluoro-4-(3-(2- fenilacetil)tioureido)fenoxi)-7-metoxi-n-metilquinolina-6-carboxa mida e hidroxipropil-b-ciclodextrina. |
CN108546244B (zh) * | 2018-07-05 | 2021-04-23 | 南昌航空大学 | 一种3,3’-二吲哚乙烷类化合物的合成方法 |
WO2022150559A1 (en) * | 2021-01-08 | 2022-07-14 | Duke University | Methods for treatment of cancer using abl inhibitors and drugs targeting the mevalonate pathway |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4522811A (en) * | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
CN101941970B (zh) * | 2005-02-09 | 2013-08-21 | 艾科优公司 | 用于治疗癌症的meleimide衍生物、药物组合物以及方法 |
AU2008239594B2 (en) | 2007-04-13 | 2013-10-24 | Beth Israel Deaconess Medical Center | Methods for treating cancer resistant to ErbB therapeutics |
WO2009002806A1 (en) * | 2007-06-22 | 2008-12-31 | Arqule, Inc. | Pyrrolidinone, pyrrolidine-2, 5-dione, pyrrolidine and thiosuccinimide derivatives, compositions and methods for treatment of cancer |
WO2009055343A2 (en) | 2007-10-22 | 2009-04-30 | Schering Corporation | Fully human anti-vegf antibodies and methods of using |
US20110104256A1 (en) | 2008-03-25 | 2011-05-05 | Yaolin Wang | Methods for treating or preventing colorectal cancer |
AU2010213696B2 (en) | 2009-02-12 | 2015-10-01 | Arqule, Inc. | A composition comprising (-) -trans-3- (5, 6-dihydro-4H-pyrrolo [3,2,1-ij] quinolin-1-yl)-4-(1H-indol-3-yl) pyrrolidine- 2, 5-dione in combination with a second anti-proliferative agent |
WO2012003421A2 (en) * | 2010-07-01 | 2012-01-05 | Arqule, Inc. | Combinational compositions and methods for treatment of cancer |
EP2611443A2 (en) * | 2010-09-01 | 2013-07-10 | ArQule, Inc. | Methods for treatment of non-small cell lung cancer |
-
2010
- 2010-02-11 AU AU2010213696A patent/AU2010213696B2/en not_active Ceased
- 2010-02-11 TW TW099104489A patent/TWI460178B/zh not_active IP Right Cessation
- 2010-02-11 CA CA2752232A patent/CA2752232C/en not_active Expired - Fee Related
- 2010-02-11 CN CN201080014223.3A patent/CN102481299B/zh not_active Expired - Fee Related
- 2010-02-11 MX MX2011008584A patent/MX2011008584A/es active IP Right Grant
- 2010-02-11 BR BRPI1007972A patent/BRPI1007972A2/pt not_active IP Right Cessation
- 2010-02-11 EP EP10704696.3A patent/EP2396003B1/en not_active Not-in-force
- 2010-02-11 US US12/704,361 patent/US20100297075A1/en not_active Abandoned
- 2010-02-11 WO PCT/US2010/023893 patent/WO2010093789A2/en active Application Filing
- 2010-02-11 KR KR1020117021339A patent/KR101620654B1/ko not_active IP Right Cessation
- 2010-02-11 JP JP2011550228A patent/JP5687209B2/ja not_active Expired - Fee Related
-
2011
- 2011-07-28 IL IL214348A patent/IL214348A/en not_active IP Right Cessation
- 2011-07-29 ZA ZA2011/05611A patent/ZA201105611B/en unknown
-
2012
- 2012-05-24 HK HK12105129.9A patent/HK1164159A1/xx not_active IP Right Cessation
-
2015
- 2015-07-24 US US14/807,939 patent/US9642847B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
AU2010213696A1 (en) | 2011-08-18 |
TW201043626A (en) | 2010-12-16 |
AU2010213696B2 (en) | 2015-10-01 |
CN102481299B (zh) | 2015-02-25 |
TWI460178B (zh) | 2014-11-11 |
JP5687209B2 (ja) | 2015-03-18 |
US20100297075A1 (en) | 2010-11-25 |
WO2010093789A2 (en) | 2010-08-19 |
CA2752232C (en) | 2016-11-22 |
CN102481299A (zh) | 2012-05-30 |
JP2012517477A (ja) | 2012-08-02 |
WO2010093789A8 (en) | 2011-03-17 |
MX2011008584A (es) | 2012-01-27 |
US20150328208A1 (en) | 2015-11-19 |
KR101620654B1 (ko) | 2016-05-12 |
CA2752232A1 (en) | 2010-08-19 |
US9642847B2 (en) | 2017-05-09 |
ZA201105611B (en) | 2012-10-31 |
IL214348A0 (en) | 2011-09-27 |
EP2396003A2 (en) | 2011-12-21 |
WO2010093789A3 (en) | 2010-12-02 |
BRPI1007972A2 (pt) | 2016-09-13 |
EP2396003B1 (en) | 2013-04-17 |
KR20110118817A (ko) | 2011-11-01 |
IL214348A (en) | 2015-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1164159A1 (en) | A composition comprising (-)-trans-3-(5,6-dihydro-4h-pyrrolo [3,2,1-ij] quinolin-1-yl)-4-(1h-indol-3-yl) pyrrolidine-2, 5-dione in combination with sorafenib, sunitinib or erlotinib | |
IL193042A0 (en) | Phenyl-cycloalkyl and phenyl-heterocyclic derivatives as sip receptor agonists | |
EP2376659A4 (en) | METHODS, COMPOSITIONS AND NEEDS FOR DETECTION OF ALLELIC VARIANTS | |
IL210722A0 (en) | Benzazepine derivatives, compositions comprising the same and uses thereof | |
ZA200805105B (en) | Substituted imidazoquinolines, imidazonaphthyridines, and imidazopyridines, compositions, and methods | |
PL2373951T3 (pl) | Pomiar średnicy na tokarkach | |
TWI347842B (en) | Tricyclic compounds, compositions, and methods | |
ZA201103590B (en) | Lipidated imidazoquinoline derivatives | |
IL211241A0 (en) | 7-azaindole derivatives | |
GB0702259D0 (en) | 7-azaindole derivatives | |
ZA201009270B (en) | Substituted pyrimido [2,1-a]isoquinolin-4-one derivatives | |
IL207372A0 (en) | Phenylpyrrole derivatives, compositions comprising the same and uses thereof | |
GB0625842D0 (en) | Indolizine derivatives | |
AP2010005202A0 (en) | Isoquinolinyl and isoindolinyl derivatives as histamines-3 antagonists | |
IL205189A (en) | 7,6-dihydro-h5-imidazo [2,1- α] imidazole-3-carboxamide and their pharmaceutical preparations | |
EP2283194A4 (en) | LOCKABLE CONTAINER ARRANGEMENT | |
IL195190A (en) | 83cd soluble for use in combination therapy with immune suppressant | |
EP2310393A4 (en) | ARTEMISININE AND DERIVATIVES THEREOF AS ANTIVIRAL AGENTS | |
IL210377A (en) | History of Naphthyridone, their preparation and their pharmaceutical preparations | |
IL207223A0 (en) | Pyrrolidinyl derivatives and uses thereof | |
PL2276347T3 (pl) | Toltrazuril o ulepszonych właściwościach rozpuszczania | |
GB0818748D0 (en) | Improvements in packaging | |
GB0702265D0 (en) | 7-Azaindole derivatives | |
IL213588A0 (en) | Naphthyridine derivatives, their preparation and pharmaceutical compositions containing them | |
IL208021A0 (en) | 2-trifluoromethylnicotinamide derivatives as hdl-cholesterol raising agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20180211 |